Search fresh public links, source activity, and ready-to-use post angles for 340B Drug Pricing.
Fresh curated links around 340B drug pricing are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
The tally reflects a 23% increase over 2024, another substantial escalation in scale for the subsidy program critics say is being abused by large nonprofit hospitals.
The Trump administration advances a claims-based rebate model for select 340B drugs as a new bipartisan Senate bill would block it, forcing health systems to track three reform pat...
A notice from the Health Resources & Services Administration sidelines covered entities' attestations of substantial administrative burden and sets the mulligan program into mo...
By Adam J. Fein, Ph.D.The 340B Drug Pricing Program continues to redefine the meaning of "skyrocketing." For 2025, discounted purchases under the 340B program reached an astound...
The Health Resources and Services Administration is again pushing to include rebates in the drug discount program after a failed attempt earlier this year. Hospitals railed against...
On July 31, 2026, the Health Resources and Services Administration (“HRSA”) announced a revised 340B Rebate Model Pilot Program (“2026 Pilot”) to provide a rebate mechanism through...
A bipartisan group of six senators introduced a bill to reform the 340B drug program, locking in hospitals’ use of contract pharmacies and adding new transparency and compliance ru...
The SUSTAIN 340B Act introduced Wednesday would bring hospital-backed changes, like a clearinghouse to handle improper discounts and codify longstanding grey areas in the contentio...
HHS is reviving a rebate program for 340B drug discounts after the previous pilot was blocked in court earlier this year. Providers say the change will burden already cash-strapped...
The ruling upheld a previous decision that pharma companies cannot impose rebates without HHS Secretary approval.
Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
By Abdie Santiago —
By Abdie Santiago —
The Pharmaceutical Care Management Association announced Thursday that its members had reached an agreement with the feds to offer information on cash prices available through Trum...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.